ESPE Abstracts (2015) 84 P-2-426

The Acid-Labile Subunit Dose Matters? Response to Human GH Treatment in Patients with Acid-Labile Subunit Deficiency

Susanne Bechtold, Julia Roeb, Claudia Weissenbacher, Carmen Sydlik & Heinrich Schmidt


University Children’s Hospital, Munich, Germany


Background: In patients with acid-labile subunit (ALS) deficiency, the inability to build ternary complexes results in a marked reduction of circulating total IGF1. Height reduction by heterozygosity is about 1 SD in comparison to wild type. In homozygosity or compound heterozygosity a height loss of −2 to −2.5 SD occurs. This is suggestive of a gene-dose effect. How does treatment with human GH influence height development in relation to the underlying genetic defect and the ALS concentration?

Patients: We report on two growth retarded boys with documented ALS deficiency. Patient 1 has a homozygous mutation and undetectable ALS and IGF1 concentrations, and patient 2 has a heterozygous mutation and low levels of ALS and IGF1. Patient 1 had an age of 6.7 years and a height of −3.03 SD and patient 2 an age of 15.8 years and a height of – 1.9 SD when GH treatment was started. After GHD exclusion the patients were treated with GH in escalating doses up to 0.05 mg/kg bw/day.

Results: Patient 1 did not profit from treatment with GH and showed no increase in height-SD. We also used recombinant IGF1 to improve his height development, without any success. There was no change in IGF1 levels throughout treatment. His near final height is −3.0 SD. Patient 2 with low, but detectable IGF1 and ALS levels improved his height during GH treatment and his final height is at −0.4 SD. During GH treatment his IGF1 levels increased.

Discussion: In patients with an absolute deficiency of ALS, treatment with either GH or IGF1 might be without use. However, those patients with low but detectable IGF1 and ALS levels, and a heterozygous mutation, might profit from GH treatment. We speculate that the ALS dose could matter when weighing treatment options in height reduction in ALS deficiency.

Article tools

My recent searches

No recent searches.